Yahoo
NasdaqGS - BOATS Real Time Price USD

ImmunityBio, Inc. (IBRX)

7.79 -0.01 (-0.13%)
At close: June 25 at 4:00:00 PM EDT
7.73 -0.06 (-0.77%)
Overnight: 10:01:12 PM EDT
Trade IBRX on Coinbase
Chart Range Bar
Loading chart for IBRX
Chart does not reflect overnight price.

News headlines ImmunityBio (IBRX) is generating significant buzz as retail traders speculate on its potential inclusion in the Russell 1000, which could trigger substantial index fund buying. The company is also gaining recognition for its promising cancer therapies, specifically ANKTIVA, while facing market volatility and scrutiny regarding its fundamentals.

ImmunityBio (IBRX) is generating significant buzz as retail traders speculate on its potential inclusion in the Russell 1000, which could trigger substantial index fund buying. The company is also gaining recognition for its promising cancer therapies, specifically ANKTIVA, while facing market volatility and scrutiny regarding its fundamentals.

Updated 38m ago · Powered by Yahoo Scout
  • Previous Close 7.80
  • Open 7.72
  • Bid 5.68 x 200
  • Ask 9.67 x 200
  • Day's Range 7.51 - 7.89
  • 52 Week Range 1.95 - 12.43
  • Volume 9,349,376
  • Avg. Volume 13,957,914
  • Market Cap (intraday) 8.159B
  • Beta (5Y Monthly) 0.10
  • PE Ratio (TTM) --
  • EPS (TTM) -0.85
  • Earnings Date (est.) Aug 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 13.00

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

immunitybio.com

684

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IBRX
293.43%
S&P 500 (^GSPC)
7.48%

1-Year Return

IBRX
182.25%
S&P 500 (^GSPC)
20.77%

3-Year Return

IBRX
189.59%
S&P 500 (^GSPC)
69.20%

5-Year Return

IBRX
46.09%
S&P 500 (^GSPC)
71.88%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 44.21M
Earnings -86.24M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-50M
0

Analyst Insights

View More

Analyst Price Targets

12.00
13.00 Average
7.79 Current
15.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/2/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 15 -> 15

Statistics

View More

Valuation Measures

Annual
As of 6/25/2026
  • Market Cap

    8.16B

  • Enterprise Value

    8.50B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    53.23

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    60.27

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.38%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    140.98M

  • Net Income Avi to Common (ttm)

    -854.53M

  • Diluted EPS (ttm)

    -0.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    380.88M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -193.7M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

7.79 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: